---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| AA | African American |
| AAPC | AAPC, a professional association for medical coding |
| AASK | African American Study of Kidney Disease and Hypertension |
| ACE | Angiotensin-converting enzyme |
| ACEi | Angiotensin-converting enzyme inhibitor |
| ACR | Albumin-to-creatinine ratio |
| AE, AEs | Adverse event |
| AHFS | American Hospital Formulary Service |
| aHR | Adjusted hazard ratio |
| AIDS | Acquired immunodeficiency syndrome |
| AJMC | The American Journal of Managed Care |
| AKI | Acute kidney injury |
| ALT | Alanine aminotransferase |
| AMKD | APOL1-mediated kidney disease |
| APOL1, ApoL1 | Apolipoprotein L1 |
| APOL1-HR | APOL1 high-risk genotype |
| APOL1-KD | APOL1 kidney disease |
| APOLLO | APOL1 Long-term Kidney Transplantation Outcomes Network |
| ARB | Angiotensin II receptor blocker |
| ARIC | Atherosclerosis Risk in Communities study |
| ART | Antiretroviral therapy |
| ASN | American Society of Nephrology |
| ASO | Antisense oligonucleotide |
| AST | Aspartate aminotransferase |
| ATP | Adenosine triphosphate |
| AUC | Area under the concentration-time curve |
| AUC0-24h, AUC0-24hr | Area under the concentration-time curve from 0 to 24 hours |
| AUC0-inf | Area under the concentration-time curve from time 0 to infinity |
| AUCtau | Area under the concentration-time curve over the dosing interval |
| AZD2373 | AstraZeneca development code for an investigational subcutaneous APOL1-directed therapy |
| BA | Bioavailability |
| BCI | Bayesian credible interval |
| BMI | Body mass index |
| BP | Blood pressure |
| BTD | Breakthrough Therapy Designation |
| CARDIA | Coronary Artery Risk Development in Young Adults study |
| CAS | Chemical Abstracts Service |
| CI | Confidence interval |
| CKD | Chronic kidney disease |
| CKD-EPI | Chronic Kidney Disease Epidemiology Collaboration |
| CLss/F | Apparent clearance at steady state |
| CNI, CNIs | Calcineurin inhibitor |
| COVAN | COVID-19-associated nephropathy |
| COVID-19 | Coronavirus disease 2019 |
| CP | Child-Pugh |
| CR | Complete remission |
| CRIC | Chronic Renal Insufficiency Cohort study |
| CTIS | Clinical Trials Information System (European Union) |
| CV | Coefficient of variation |
| CVD | Cardiovascular disease |
| CYP3A, CYP3A4 | Cytochrome P450 3A, cytochrome P450 3A4 |
| DAPA-CKD | Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease trial |
| DDI | Drug-drug interaction |
| DDKTs | Deceased donor kidney transplants |
| DRI | Direct renin inhibitor |
| EC50 | Half-maximal effective concentration |
| ECG, ECGs | Electrocardiogram |
| EE | Ethinyl estradiol |
| eGFR | Estimated glomerular filtration rate |
| EHR | Electronic health record |
| EMA | European Medicines Agency |
| ER | Endoplasmic reticulum |
| ERAs | Endothelin receptor antagonists |
| ESKD | End-stage kidney disease |
| ESRD | End-stage renal disease |
| EU | European Union |
| FAS | Full Analysis Set |
| FDA | U.S. Food and Drug Administration |
| FET | Fisher's exact test |
| FFS | Fee-for-service |
| FIH | First in human |
| FSGS | Focal segmental glomerulosclerosis |
| G0 | APOL1 reference (non-risk) allele |
| G1, G2 | APOL1 kidney risk variant alleles |
| GFR | Glomerular filtration rate |
| GLP-1 | Glucagon-like peptide-1 |
| GLSMR | Geometric least squares mean ratio |
| GMPC | Geometric mean percent change |
| GMR | Geometric mean ratio |
| H-ESKD | Hypertension-attributed end-stage kidney disease |
| HAART | Highly active antiretroviral therapy |
| HCV | Hepatitis C virus |
| HD | Hemodialysis |
| HDL | High-density lipoprotein |
| HEDIS | Healthcare Effectiveness Data and Information Set |
| HIV | Human immunodeficiency virus |
| HIVAN | HIV-associated nephropathy |
| HR | Hazard ratio |
| HRQoL, HRQOL | Health-related quality of life |
| HTA | Health technology assessment |
| IA | Interim analysis |
| IC50 | Half-maximal inhibitory concentration |
| ICD-10-CM | International Classification of Diseases, Tenth Revision, Clinical Modification |
| ICER | Institute for Clinical and Economic Review |
| ICF | Informed consent form |
| IDMC | Independent Data Monitoring Committee |
| IFN-γ | Interferon gamma |
| IgAN | Immunoglobulin A nephropathy |
| IgAV | Immunoglobulin A vasculitis |
| IHD | In-center hemodialysis |
| INN | International Nonproprietary Name |
| IQR | Interquartile range |
| IRB | Institutional review board |
| IXP | Inaxaplin |
| KDIGO | Kidney Disease: Improving Global Outcomes |
| KDOC | Kidney Donor Outcomes Cohort study |
| KED | Kidney Health Evaluation for Patients With Diabetes (HEDIS measure) |
| KRT | Kidney replacement therapy |
| LDL | Low-density lipoprotein |
| LKDs | Living kidney donors |
| LN | Levonorgestrel (with EE); lupus nephritis |
| MA | Medicare Advantage |
| MAD | Multiple ascending dose |
| MAP | Mean arterial pressure |
| MRA, MRAs | Mineralocorticoid receptor antagonist |
| mRNA | Messenger ribonucleic acid |
| MVP | Million Veteran Program |
| MZE829 | Maze Therapeutics development code for an investigational oral APOL1 inhibitor |
| NCQA | National Committee for Quality Assurance |
| NEJM | The New England Journal of Medicine |
| NIH | National Institutes of Health |
| NKF | National Kidney Foundation |
| OPOs | Organ procurement organizations |
| OR | Odds ratio |
| PCR | Protein-to-creatinine ratio |
| PD | Pharmacodynamics; peritoneal dialysis |
| PedsQL | Pediatric Quality of Life Inventory |
| Ph2, Ph3 | Phase 2, phase 3 |
| PIP | Paediatric investigation plan |
| PK | Pharmacokinetics |
| PM | Plasma membrane |
| PPPY | Per person per year |
| PRIME | PRIority MEdicines scheme (European Medicines Agency) |
| PRO | Patient-reported outcome |
| PROMIS | Patient-Reported Outcomes Measurement Information System |
| QoL | Quality of life |
| QTcF | QT interval corrected for heart rate by Fridericia's formula |
| R2 | Coefficient of determination |
| RA | Risk alleles |
| RAAS | Renin-angiotensin-aldosterone system |
| RAS | Renin-angiotensin system |
| RASi | Renin-angiotensin system inhibitor |
| RCTs | Randomized controlled trials |
| REMS | Risk Evaluation and Mitigation Strategy |
| RNA | Ribonucleic acid |
| RPD | Rare Pediatric Disease designation |
| RRVs | Renal risk variants |
| RWD | Real-world data |
| SAD | Single ascending dose |
| SAEs | Serious adverse events |
| SBP | Systolic blood pressure |
| SC | Subcutaneous |
| SD | Standard deviation |
| SF-12, SF-36 | 12-item and 36-item Short Form Health Surveys |
| SFUV | Safety follow-up visit |
| SGLT2 | Sodium-glucose cotransporter-2 |
| SGLT2i | Sodium-glucose cotransporter-2 inhibitor |
| SLE | Systemic lupus erythematosus |
| SRNS | Steroid-resistant nephrotic syndrome |
| suPAR | Soluble urokinase plasminogen activator receptor |
| T2D, T2DM | Type 2 diabetes mellitus |
| TEAEs | Treatment-emergent adverse events |
| TRAEs | Treatment-related adverse events |
| TSQM | Treatment Satisfaction Questionnaire for Medication |
| UACR, uACR | Urine albumin-to-creatinine ratio |
| uKF | Unexplained kidney failure |
| ULN | Upper limit of normal |
| UPCR | Urine protein-to-creatinine ratio |
| US | United States |
| USRDS | United States Renal Data System |
| VX-147 | Vertex Pharmaceuticals development code for inaxaplin |
| VX-840 | Vertex Pharmaceuticals development code for a second investigational APOL1 inhibitor |
| WHO | World Health Organization |
| WT | Wild type |

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
